Biotech | April 03, 2022
New data indicate molnupiravir eliminates Covid-19 rapidly
Among patients with infectious virus at baseline, no patients who received Lagevrio had infectious virus at days 3, 5 or 10
Among patients with infectious virus at baseline, no patients who received Lagevrio had infectious virus at days 3, 5 or 10
No new studies have been requested
The summit also saw the launch of two important reports- Multi-Regional Clinical Trials (MRCT) and Value of OTC in India
The award also follows GenScript's recognition at the Korea Bioprocessing Excellence Awards in 2021 for the "Best Contract Development and Manufacturing Organization Award".
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
Vault PromoMats helps life sciences companies speed the creation, review, and distribution of compliant content. Built-in digital asset management enables content reuse and reduces spend on promotional materials
The accelerated use of technology in clinical trials and the shift towards virtual trials is here to stay
It is the fourth vaccine to get the nod for 12 years and older after Biological E’s Corbevax, Bharat Biotech’s Covaxin and Zydus Lifesciences Zy-CoV-D
Subscribe To Our Newsletter & Stay Updated
